Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b study of IAM1363 in HER2-altered cancers
NL-OMON59715Phase 1Recruiting
- Sponsor
- Iambic Therapeutics
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IAM1363 in HER2-positive cancer (HER2+) and cancer, sponsored by Iambic Therapeutics. Primary endpoint: Primary endpoint(s). Started Nov 2025; status: recruiting.
02
Drugs
IAM1363
03
Conditions
HER2-positive cancer (HER2+)cancer
Beyond the preview
Go deeper on NL-OMON59715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59715.